{"entity":{"id":"nct07237100","kind":"trial","name":"Mirdametinib in Patients With Advanced NF1-mutant Melanoma","aka":[],"tldr":"A phase 2 trial of Mirdametinib in Advanced melanoma, run by Kevin Kim, MD, now recruiting.","summary":"Mirdametinib in Patients With Advanced NF1-mutant Melanoma is a phase 2 interventional study registered as NCT07237100 by Kevin Kim, MD, with 10 participants planned, started 2025-10-13 and due to reach its primary completion in 2027-10-13. Interventions recorded: Mirdametinib. Conditions recorded: Advanced Unresectable Melanoma, Metastatic Melanoma.\n\nLinked to the drug Mirdametinib because the registry names it among its interventions and Advanced melanoma among its conditions. Registry record only: no result has been read by an editor.","status":"recruiting","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT07237100","url":"https://clinicaltrials.gov/study/NCT07237100"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["advanced-melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["mirdametinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07237100","phase":"2","setting":"A Pilot Study of Mirdametinib in Patients With Advanced Melanoma With an NF1 Mutation","sponsor":"Kevin Kim, MD","enrolled":10,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07237100/","neighbours":{"cancer":[{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/"}],"drug":[{"id":"mirdametinib","kind":"drug","name":"Mirdametinib","route":"/drugs/mirdametinib/"}]}}